PVP Labs Invited to Present Taphalgin (Lumekefamide) at the 2026 Pain Therapeutics Summit Europe; Announces Key DEA Regulatory Determination
At PVP Labs, our mission has…
SAN FRANCISCO, January 12, 2026 — PVP Labs will present its lead investigational candidate, Taphalgin® (lumekefamide), a tetrapeptide analgesic platform, to institutional investors and strategic partners…
The integration of artificial intelligence into peptide design is rapidly reshaping the landscape of drug discovery. For decades, the pharmaceutical industry has grappled with a…
The peptide synthesis market is projected to reach over USD 1,066.7 million by 2032, reflecting robust growth driven by advances in peptide therapeutics and the…
Bioduro has announced the launch of a dedicated peptide business unit, marking a strategic expansion in their peptide research capabilities. This new unit is designed…
The field of peptide therapeutics continues to expand rapidly, with recent breakthroughs in peptide drugs highlighting the potential of these molecules in modern medicine. Advances…